0LB2
vs
S&P 500
0LB2
S&P 500
In den letzten 12 Monate hat 0LB2 schlechter abgeschnitten als S&P 500, und erzielte eine Rendite von +7% gegenüber S&P 500 +28% Anstieg.
Aktienperformance
0LB2 vs S&P 500
Performance-Unterschied
0LB2 vs S&P 500
Performance nach Jahr
0LB2 vs S&P 500
Vergleichen Sie die Rendite der Aktie mit ihrem Benchmark-Index und Wettbewerbern. Erhalten Sie Einblicke in die relative Performance im Zeitverlauf.
Performance der Wettbewerber
Supernus Pharmaceuticals Inc vs Wettbewerber
Supernus Pharmaceuticals Inc
Kurzüberblick
Supernus Pharmaceuticals is a specialty drug company that makes prescription medicines for central nervous system disorders, especially attention deficit hyperactivity disorder, epilepsy, migraine, and movement disorders. Its main products are branded medicines sold through pharmacies to patients with prescriptions from doctors. The company earns money when wholesalers and pharmacies buy those drugs and move them into the prescription chain. Its customer base is mostly patients, prescribers, pharmacies, and drug wholesalers, with doctors playing a key role because they decide which treatment to use. Supernus also develops and markets medicines that can be taken on a regular schedule or in specific long-acting forms, which matters in conditions where steady symptom control is important. In some cases, it also works with other drug companies through licensing or commercialization agreements. What makes Supernus different is that it focuses on a narrow set of brain and nervous system conditions rather than a broad menu of medicines. That gives it a business built around a few specialized brands, close relationships with doctors who treat these disorders, and a strong dependence on prescription demand and patent-protected products.
